|
|
 |
 |
| |
 Printable version |
Radioembolization of primary and secondary liver tumors |
Hépato-Gastro. Volume 19, Number 4, 231-8, Avril 2012, Mini-revue
|
 Résumé
Texte intégral
|
Author(s) : Olivier Dubreuil, Aziz Zaanan, Isabelle Trouilloud, Marc Sapoval, Olivier Pellerin, Sameh Awad, Nadia Ghazzar, Céline Lepère, Philippe Rougier, Julien Taieb |
Summary : Radioembolization (RE) is a complex technique, requiring oncologists, interventional radiologists and nuclear medicine physicians, which allows to deliver in the liver, via the arterial blood flow, microspheres loaded with radioactive Yttrium. This treatment is possible after very precise radiological steps in order to treat the tumors the best as possible, while avoiding an irradiation of the healthy organs. In hepatocellular carcinoma (HCC), RE has almost the same indications as chemo-embolization. But, in small studies, without direct comparison between the two treatments, RE would have fewer side effects (asthenia, nauseas, abnormality of hepatic tests…), with a similarly efficacy. Unlike chemoembolization, RE can be used in patients with portal vein thrombosis, without major complication. In colorectal cancer liver metastases, RE has been studied in last therapeutic option, after progression under usual treatments, and the results show an improvement in time to liver progression, which can be doubled, and in response rates which fluctuate between 10 and 20%. It has equally been tested in first line, in small samples studies, but with interesting results which led to randomized phase III studies, still ongoing. RE has interesting results in poor methodology studies, and could be a useful treatment in the future, in the HCC and in liver metastases of colorectal cancers. |
Keywords : radioembolization, hepatocellular carcinoma, liver metastases, yttrium 90 |
|
